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Background: In Changhua County, Taiwan, the number of clinical Acinetobacter baumannii isolates has risen since
2002, and multidrug-resistant Acinetobacter baumannii (MDRAB) has spread rapidly throughout Taiwan. In this study,
to reveal the mechanism involved with the rapid dissemination of MDRAB emergence, the utility of the class 1 integron,
intI1 integrase gene, as an MDRAB-associated biomarker was examined. A cross-sectional, clinical epidemiological study
was performed at Changhua Christian Hospital between January 1st, 2001 and December 31st, 2004. Besides the
existence of intI1 gene was examined, the pulse-field gel electrophoresis (PFGE) was also performed to determine the
epidemiological characteristics of the isolates.
Findings: The overall hospital infection rate was 5–6%, while the infection rate of the intensive care unit (ICU)
fluctuated. No positive correlation was observed between MDRAB isolates and the presence of intI1 (r = 0.168,
P = 0.254). Additionally, no positive correlation was observed between the infection rate in the ICU and the presence
of intI1 (r = −0.107, P = 0.468) or between the hospital infection rate and the presence of intI1 (r = −0.189, P = 0.199).
However, two predominant clones among the MDRAB isolates were identified by PFGE.
Conclusions: Although the presence of the intI1 gene does not seem suitable for tracing MDRAB emergence in
Changhua County, two predominant clones were identified by PFGE, and subsequent studies to identify whether these
clones were responsible for original nosocomial infection are needed.
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Introduction
Multidrug-resistant Acinetobacter baumannii (MDRAB)
is globally recognized as an important cause of nosocomial
infections during this century [1]. Both environmental
adaptation and rapid acquisition of resistance genes have
contributed to the ability of Acinetobacter baumannii
(AB) to be such a prosperous pathogen [2]. These resist-
ance genes are primarily spread through horizontal gene
transfer (HGT) of plasmids, transposons, or integrons that
carry gene clusters that provide resistance to several anti-
biotic families [3]. Resistance islands (RIs) are important
elements for acquiring foreign genes by HGT [4]. The* Correspondence: cchuang@dragon.nchu.edu.tw
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article, unless otherwise stated.RIs containing the integrons have been reported in many
MDRAB strains [5-8]. Within Changhua County (CC),
Taiwan, the numbers of clinical AB isolates have risen
since 2002, and the first MDRAB was reported in Taiwan
that same year [9]. Since then, MDRAB has rapidly spread
through Taiwan and been an emerging problem. Though
early detection is critical for isolation and targeted ther-
apy, no well-known biomarker for detecting those mobile
characteristics exists because of the structural diver-
sity of RIs of AB. On the other hand, the class 1 integron-
carrying MDRAB clones were reported to be widespread
in Taiwan [10], while Koeleman showed that amplifica-
tion of the IntI gene may act as a rapid and simple
technique for the routine screening and identification
of clinical A. baumannii isolates with epidemic potential
[11]. Another study showed that integron detection could
be a useful tool for studying molecular epidemiology in
hospital environments, facilitating the quick detection ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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such as the intensive care unit (ICU). To reveal the mech-
anism involved with the rapid dissemination of MDRAB
emergence, the presence of the intI1 integrase gene in
class 1 integrons was assessed as an MDRAB-associated
biomarker in this study.
Methods
Clinical investigations
The Changhua Christian Hospital (CCH) is an 1800-bed
tertiary teaching hospital located at CC, Central Taiwan.
A cross-sectional, epidemiological study of MDRAB isolates
was conducted at CCH from January 1st, 2001 to December
31st, 2004. Infectious disease specialists reviewed all pa-
tient medical records. Because and our findings disclosed
MDRAB, which were resistant to many broad-spectrum
antibiotics (including ciprofloxacin, piperacillin-tazobactam,
ceftazidime, cefepime, imipenem-cilastatin, amikacin) since
2001–2002 and we reviewed literature (Additional file 1),
the critical period for the appearance and spread of
MDRAB was estimated to be 2001–2002. We choose the
study year is 2001–2002 with the hypothesis of study year
is the beginning of the increment of resistant A. bauman-
nii infection. Concerning the observation year, we selected
the 2003–2004 for comparison. If the hypothesis is cor-
rect, the presence of the intI1 integrase gene in class 1
integrons will increase between the study year and the ob-
servation year. The Standard Centers for Disease Control
and Prevention National Nosocomial Infections Surveil-
lance definitions for nosocomial infections were used [13].
The hospital infection rate and the ICU infection rate
were calculated. We also performed retrospective surveil-
lance for nosocomial infections in the ICUs.
Microbiological investigations
All AB isolates were routinely examined at Medical La-
boratory Department of CCH and stored in the Bacterial
Bank of CCH from January 1st, 2001 to December 31st,
2004. Phenotypic methods were used to identify A. bau-
mannii isolates using a Vitek-2 System (BioMerieux,
Marcy l'Etoile, France). Additionally, antimicrobial sus-
ceptibility was determined using an automated Vitek 2
(bioMe'rieux, Marcy l'Étoile, France) according to the
recommendations of Clinical and Laboratory Standards
Institute [14]. In this study, MDRAB was defined as re-
sistance to at least two specific representatives of at least
two classes of antibiotics among those antibiotic categories,
including aminoglycosides, anti-pseudomonal penicillins,
carbapenems, third or fourth generation cephalosporins
and quinolones [15].
Molecular detection of IntI1 integrase gene
As previously described, the Koeleman’s method was used
to amplify the targeted intI1 gene [11]. We used randomsampling methods for the retrospective analysis during
January 1st, 2001 to December 31st, 2004, and a half of
clinical MDRAB isolates monthly were selected, but no
more than 10 isolates among each months, during the
study period. Overall 440 MDRAB isolates were tested for
the target gene intI1 during the study period.
Pulse-field gel electrophoresis (PFGE) analysis
The ampicillin-sulbactam resistance phenotype, IntI1 inte-
grase positive genotype, and strains isolated within season
of high infection rate were chosen as the selection criteria
for listing candidates MDRAB strains. Standard protocol
for PFGE analysis was employed for the A. baumannii iso-
lates. Briefly A. baumannii were plated on blood agar and
incubated in a 5% CO2 atmosphere at 35°C for 16–24 h.
Plug slices were digested with 20 U of SgrAI. The DNA
fragments were then separated in 1% Seakem Gold agarose
gels (FMC BioProducts) at 14°C using a Bio-Rad CHEF
DRIII PFGE system (Bio-Rad Laboratories, Hercules, CA,
USA). Gels were run in 0.5× Tris-borate-EDTA (TBE;
pH 8) at a 120° fixed angle and a fixed voltage (6 V/cm),
with pulse intervals from 4–40 s for 20 h. Following stain-
ing and imaging, the chromosomal DNA restriction pat-
terns produced by PFGE were interpreted using Tenover’s
categorization [16].
Statistical analysis
We used the finite mixture model on categorical dataset
of antibiotic resistance phenotypes. The results were con-
sidered significant when the P value was less than 0.05.
All data were analyzed using a SPSS software v10.0. We
used the χ2 test on categorical data to analyze relations.
We used the Spearman’s correlation to analyze the rela-
tions between different parameters.
Results
During the past fifteen years, the overall hospital infec-
tion rate at CCH was 5-6%, and the infection rate in the
ICU fluctuated. During this time period, patients with
AB infections increased gradually at CCH, especially in
the ICU (data not shown). Between January 1st, 2001 and
December 31st, 2004, two periods occurred during which
the number of AB-infected patients increased. The Infec-
tion Control Office of CCH began to investigate the infec-
tion rate in the hospital and the ICU (Additional file 2).
Several periods occurred during which the infection rate
in the ICU increased, including June 2001, November
2001, February 2002, July 2002, September 2002, July
2003, November 2003, and March 2004. However, the
reason for the gradual increase in AB infection is still un-
known, despite investigation. No significant changes in
the numbers of MDRAB isolates and the carrying rate of
IntI1 gene were observed when the data from 2001–2002
was compared to that of 2003–2004.
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the results of amplifying the IntI1 gene from clinical 440
MDRAB isolates are shown in Table 1. No positive cor-
relation was observed between clinical MDRAB isolates
and the presence of the IntI1 in the bacteria (r = 0.168,
P = 0.254). Additionally, no positive correlation was ob-
served between the infection rate in the ICU and the
presence of IntI1 (r = −0.107, P = 0.468). Furthermore, no
positive correlation was observed between the rate of hos-
pital infection and the presence of integron (r = −0.189,
P = 0.199). Thus, the presence of IntI1 integrase gene
does not correlate with MDRAB prevalence and spread
during the study period.
To evaluate the epidemiological features of the MDRAB
isolates, selection criteria such as ampicillin-sulbactam
resistance phenotype, IntI1 integrase positive genotype,
and strains isolated within season of high infection rate
were used for choosing candidates MDRAB strains (Table 2)
Eight of the clinical MDRAB isolates (two isolates each
year), which carried IntI1 positive genotype and ampicillin-
sulbactam resistance phenotypes were chosen in each July
during the four study years. And, the other four clinical
MDRAB isolates (one isolate each year), which is resistant
to ampicillin-sulbactam but without carrying IntI1 gene,
were also employed as reference strains during the same
study period. The interpretation method for PFGE re-
sults is according to Tenover’s criteria [16], and the
statistic method is descriptive method (Table 2). Though
PFGE results identified two predominant clones types
(clone A, B) during the study year (Table 2, Additional
file 3), the relationships between the predominant clones
and the presence of the IntI1 did not have a significant
association.Table 1 Epidemiological features of the ICU infection rate,
hospital infection rate, clinical multidrug-resistant A.
baumannii isolate numbers and IntI1-containing rate










2001 r 0.080 −0.235 −0.586
p-value 0.805 0.462 0.045
2002 r 0.055 −0.088 −0.228
p-value 0.864 0.785 0.476
2003 r 0.594 0.041 0.305
p-value 0.042 0.899 0.334
2004 r −0.086 −0.172 −0.135
p-value 0.790 0.594 0.675
Overall r 0.168 −0.107 −0.189
p-value 0.254 0.468 0.199
Notes: r: Spearman’s Correlation Coefficient, MDRAB: Multi-drug resistant
A. baumannii.Discussion
This study is the first epidemiological study to evaluate
the involvement of class 1 integron for the appearance
and spread of MDRAB in central Taiwan. MDRAB has
been reported in Taiwan since the early 21st century [17],
and we also disclosed the same trend of MDRAB at the
CCH. After evidence-based literature review (Additional
file 1), 2001–2002 was identified as the critical time period
for the appearance and spread of MDRAB, so we engaged
this study. Because of the structural diversity of RIs in AB,
detecting these huge mobile elements is not simple. The
epidemic class 1 integron-carrying MDRAB clone was re-
ported in Taiwan [10]. Detection of this class 1 integron,
which is located in an RI of AB, is convenient. To reveal
the mechanism and to trace the rapid dissemination
during the emergence of MDRAB, we choose the IntI1
integrase gene as the target for detection. However, the
presence of IntI1 does not correlate with the emergence
and spread of MDRAB in this study. The IntI1 gene is
present in 81.3% of clinical AB isolates at our institute [9]
and 66.7% at Zhong’s study [18].
In this study, we reported that the presence of IntI1
does not correlate with the emergence and spread of
MDRAB, and it’s different from previous study [19]. The
reasons for no correlation between the intl1 gene and
MDRAB could be multiple factors in this study. Firstly,
since the structural complexity of RIs, the IntI1 gene
may be not a good marker to trace the appearance and
spread of MDRAB prior to the dissemination of class 1
integron-carrying MDRAB clones. Secondly, IntI1 is too
common to be an accurate biological marker. The contri-
butions of class 1 integrons in MDRAB involve their car-
ried antibiotic cassettes. So, the presence of IntI1 integrase
gene along does not correlate with the emergence and
spread of MDRAB in this study. Further examinations
were needed to reveal the correlation between their anti-
biotic cassettes and emergence of MDRAB.
The susceptibility rates of sulbactam-containing combi-
nations (such as ampicillin-sulbactam) for AB were 90.4–
92.7% in Brauers’s study [20], but the resistance rate of
sulbactam-containing combinations (such as ampicillin-
sulbactam) for AB was 57.4-64.1% in Taiwan Surveillance
of Antimicrobial Resistance program [21]. The resistant
rates to piperacillin/tazobactam and third geenration
cephalosporines and fluoroquinolones for MDRAB strains
in Taiwan were around 75%, while the resistant rates to
ampicillin-sulbactam for MDRAB strains in Taiwan was
only 50% [21]. Since sulbactam resistance phenotpye of
AB was shown to be unique in Taiwanese isolates, the
resistance phenotpye of ampicillin-sulbactam was thus
chosen as selection criteria for PFGE analysis candidates.
With regard to genotyping for AB, PFGE, multilocus se-
quence typing, and rep-PCR have been used in previous
studies [22-24], while PFGE is still considered as the
Table 2 Summary for results of PFGE fingerprint patterns and antibiotic susceptibility among clinical Acinetobacter
baumannii isolates in the PFGE study
Number P11 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12
Isolates year 2001 2001 2002 2002 2003 2003 2004 2004 2001 2002 2003 2004
PFGE type A B C B A A B D A A E A
Carrying-Int I1 + + + + + + + + - - - -
AN R2 R R R R S R R R S R S
SAM R R R R R R R R R R R R
CTZ S S R S R S R S R S S R
LVF S S S S S S S S S S S S
IMP S S S S S S R S S S R S
PIP-TAZ S R S R S R S R S R S S
CRO S S R S R S R S R S S R
Notes:
1P number is the Lane number of PFGE study.
2S: Susceptible; R: Resistant; I: Belonged to resistant.
3The susceptibility tests were performed using the Vitek-2 GN card (Biomerieux, Marcy l'Etoile, France). The results were interpreted using the CLSI breakpoints
(Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility testing).
4Abbreviation AN: amikacin; SAM: Ampicillin-sulbactam; CTZ: Ceftazidime; LVF: Levofloxacin; IMP: Imipenem-cilastatin; PIP-TAZ: Piperacillin-tazobactam; CRO: Ceftriaxone;
colistin and tigecycline and polymyxin B were not provided by Vitek-2 System.
Chen and Huang Journal of Negative Results in BioMedicine 2014, 13:15 Page 4 of 6
http://www.jnrbm.com/content/13/1/15common standard for typing the outbreak-related isolates
of AB [19]. In this study, PFGE results identified two pre-
dominant clones (clone A, B) (Figure 1) during the
epidemic season. The result supports that PFGE is more
accurate than IntI1-PCR to differentiate MDRAB isolates
in central Taiwan. In this study, the reasons to choose
three kinds of selection marker are as following: The first
one is ampicillin/sulbactam resistant phenotype. Ampicillin/
sulbactam has been proven to be more efficacious than
polymyxins in treating carbapenem-resistant A. baumannii
infection [25]. Although resistance to ampicillin/sulbactam
in A. baumannii has been reported in many countries
[1] and authors disclosed one unique phenomenon is
that some isolates of MDRAB, which were resistant to
many broad-spectrum antibiotics (including ciprofloxacin,
piperacillin-tazobactam, ceftazidime, cefepime, imipenem-Figure 1 PFGE fingerprints of 12 multi-resistant A. baumannii (MDRAcilastatin, amikacin) but susceptible to ampicillin/sulbactam
between 2001 and 2002 [9]. No resistance mechanism was
described in those studies. The second marker is intI1
integrase gene in class 1 integrons, and that is the target
gene in this study. The last marker is timeline with recru-
descent tendency. Because of a lot of clinical A. bauman-
nii isolates, we needed to select the important isolates
to study. According to the Additional file 2 (which
shows the infection rate of the hospital and the ICU
during 2001–2004), the strains isolated within season
of high infection rate are from summer season during the
four study period. It would be interesting to know how
many of the nosocomial or healthcare-associated MDRAB
isolates belongs to the same fingerprint type, and we should
be cautious to those predominant clones, which spreading
among hospitals and disseminating their integrons involvedB) isolates with resistance to ampicillin-sulbactam.
Chen and Huang Journal of Negative Results in BioMedicine 2014, 13:15 Page 5 of 6
http://www.jnrbm.com/content/13/1/15gene cassettes. Further examinations are needed to reveal
the facts.
Concerning infection rate of the hospital and the ICU,
it was also examined in this study (Table 1, Additional
file 2). Several periods occurred during which the infec-
tion rate in the ICU increased, including June 2001,
November 2001, February 2002, July 2002, September
2002, July 2003, November 2003, and March 2004. New
staff has begun to work after orientation and training in
June and September since 1990 at our institute. Addition-
ally, budget cuts resulted in downsizing and changes in
staffing, and many buildings were erected at our institute.
Thus, further study is needed to elucidate the reasons and
factors for the increase in clinical MDRAB isolates at cen-
tral Taiwan at the period of the early 21st century.
Conclusion
In this study, the emergence of MDRAB in a Taiwanese
hospital was traced by the correlated between detection
of IntI1 and existence of MDRAB. This is the first cross-
sectional, clinical epidemiological study on the involve-
ment of class 1 integron in the emergence and spread
of MDRAB in Central Taiwan. Though the existence of
intI1 gene is not suitable for tracing MDRAB emergence
that occurred at CCH, two predominant clones were iden-
tified from PFGE study, and subsequent studies to deter-
mine whether these clones are responsible for the original
nosocomial infection are needed.
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